STOCK TITAN

[6-K] Haleon plc American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Haleon plc (LSE/NYSE: HLN) filed a Form 6-K to disclose its share capital position as of 30 June 2025. The Company has issued 8,988,533,553 ordinary shares of £0.01 each, of which 3,880,205 are held in treasury. Consequently, the number of ordinary shares carrying voting rights is 8,984,653,348. This denominator should be used by investors to determine whether their holdings trigger disclosure obligations under the FCA’s Disclosure Guidance and Transparency Rules. No other financial data, corporate actions or strategic updates were included in the filing.

Haleon plc (LSE/NYSE: HLN) ha depositato un Modulo 6-K per comunicare la situazione del proprio capitale sociale al 30 giugno 2025. La Società ha emesso 8.988.533.553 azioni ordinarie del valore nominale di £0,01 ciascuna, di cui 3.880.205 sono detenute in tesoreria. Di conseguenza, il numero di azioni ordinarie con diritto di voto è pari a 8.984.653.348. Questo numero deve essere utilizzato dagli investitori per determinare se le loro partecipazioni superano le soglie di comunicazione previste dalle norme FCA sulla divulgazione e trasparenza. Nel deposito non sono stati inclusi altri dati finanziari, azioni societarie o aggiornamenti strategici.

Haleon plc (LSE/NYSE: HLN) presentó un Formulario 6-K para revelar su posición de capital social al 30 de junio de 2025. La Compañía ha emitido 8.988.533.553 acciones ordinarias de £0,01 cada una, de las cuales 3.880.205 están en tesorería. Por lo tanto, el número de acciones ordinarias con derecho a voto es 8.984.653.348. Este denominador debe ser utilizado por los inversores para determinar si sus participaciones activan obligaciones de divulgación bajo las Reglas de Divulgación y Transparencia de la FCA. No se incluyeron otros datos financieros, acciones corporativas ni actualizaciones estratégicas en la presentación.

Haleon plc (LSE/NYSE: HLN)는 2025년 6월 30일 기준 주식 자본 현황을 공개하기 위해 Form 6-K를 제출했습니다. 회사는 액면가 £0.01의 보통주 8,988,533,553주를 발행했으며, 그 중 3,880,205주는 자사주로 보유 중입니다. 따라서 의결권이 있는 보통주의 수는 8,984,653,348주입니다. 투자자들은 FCA의 공시 및 투명성 규정에 따른 공시 의무 발생 여부를 판단할 때 이 수치를 기준으로 삼아야 합니다. 제출 서류에는 기타 재무 데이터, 기업 활동 또는 전략적 업데이트는 포함되지 않았습니다.

Haleon plc (LSE/NYSE : HLN) a déposé un formulaire 6-K pour divulguer sa position de capital social au 30 juin 2025. La société a émis 8 988 533 553 actions ordinaires d’une valeur nominale de £0,01 chacune, dont 3 880 205 sont détenues en trésorerie. Par conséquent, le nombre d’actions ordinaires avec droit de vote est de 8 984 653 348. Ce dénominateur doit être utilisé par les investisseurs pour déterminer si leurs participations déclenchent des obligations de divulgation selon les règles de transparence et de communication de la FCA. Aucun autre renseignement financier, action corporative ou mise à jour stratégique n’a été inclus dans le dépôt.

Haleon plc (LSE/NYSE: HLN) hat ein Formular 6-K eingereicht, um seine Kapitalstruktur zum 30. Juni 2025 offenzulegen. Das Unternehmen hat 8.988.533.553 Stammaktien mit einem Nennwert von jeweils £0,01 ausgegeben, von denen 3.880.205 als eigene Aktien gehalten werden. Folglich beträgt die Anzahl der stimmberechtigten Stammaktien 8.984.653.348. Diese Zahl sollten Anleger verwenden, um zu bestimmen, ob ihre Beteiligungen Meldepflichten gemäß den Offenlegungs- und Transparenzregeln der FCA auslösen. Weitere Finanzdaten, Unternehmensmaßnahmen oder strategische Updates wurden in der Einreichung nicht enthalten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine share-count update; no immediate valuation impact, but essential for regulatory threshold calculations.

The 6-K solely updates Haleon’s share count and voting rights. Treasury shares represent roughly 0.04 % of issued stock, leaving an effective float of 8.985 billion shares. Because no buy-back, capital raise, or earnings information is disclosed, the filing is operationally neutral. Nevertheless, accurate denominators are critical for institutional investors monitoring 3 % and 5 % disclosure thresholds under UK and FCA rules. Overall market impact is negligible.

Haleon plc (LSE/NYSE: HLN) ha depositato un Modulo 6-K per comunicare la situazione del proprio capitale sociale al 30 giugno 2025. La Società ha emesso 8.988.533.553 azioni ordinarie del valore nominale di £0,01 ciascuna, di cui 3.880.205 sono detenute in tesoreria. Di conseguenza, il numero di azioni ordinarie con diritto di voto è pari a 8.984.653.348. Questo numero deve essere utilizzato dagli investitori per determinare se le loro partecipazioni superano le soglie di comunicazione previste dalle norme FCA sulla divulgazione e trasparenza. Nel deposito non sono stati inclusi altri dati finanziari, azioni societarie o aggiornamenti strategici.

Haleon plc (LSE/NYSE: HLN) presentó un Formulario 6-K para revelar su posición de capital social al 30 de junio de 2025. La Compañía ha emitido 8.988.533.553 acciones ordinarias de £0,01 cada una, de las cuales 3.880.205 están en tesorería. Por lo tanto, el número de acciones ordinarias con derecho a voto es 8.984.653.348. Este denominador debe ser utilizado por los inversores para determinar si sus participaciones activan obligaciones de divulgación bajo las Reglas de Divulgación y Transparencia de la FCA. No se incluyeron otros datos financieros, acciones corporativas ni actualizaciones estratégicas en la presentación.

Haleon plc (LSE/NYSE: HLN)는 2025년 6월 30일 기준 주식 자본 현황을 공개하기 위해 Form 6-K를 제출했습니다. 회사는 액면가 £0.01의 보통주 8,988,533,553주를 발행했으며, 그 중 3,880,205주는 자사주로 보유 중입니다. 따라서 의결권이 있는 보통주의 수는 8,984,653,348주입니다. 투자자들은 FCA의 공시 및 투명성 규정에 따른 공시 의무 발생 여부를 판단할 때 이 수치를 기준으로 삼아야 합니다. 제출 서류에는 기타 재무 데이터, 기업 활동 또는 전략적 업데이트는 포함되지 않았습니다.

Haleon plc (LSE/NYSE : HLN) a déposé un formulaire 6-K pour divulguer sa position de capital social au 30 juin 2025. La société a émis 8 988 533 553 actions ordinaires d’une valeur nominale de £0,01 chacune, dont 3 880 205 sont détenues en trésorerie. Par conséquent, le nombre d’actions ordinaires avec droit de vote est de 8 984 653 348. Ce dénominateur doit être utilisé par les investisseurs pour déterminer si leurs participations déclenchent des obligations de divulgation selon les règles de transparence et de communication de la FCA. Aucun autre renseignement financier, action corporative ou mise à jour stratégique n’a été inclus dans le dépôt.

Haleon plc (LSE/NYSE: HLN) hat ein Formular 6-K eingereicht, um seine Kapitalstruktur zum 30. Juni 2025 offenzulegen. Das Unternehmen hat 8.988.533.553 Stammaktien mit einem Nennwert von jeweils £0,01 ausgegeben, von denen 3.880.205 als eigene Aktien gehalten werden. Folglich beträgt die Anzahl der stimmberechtigten Stammaktien 8.984.653.348. Diese Zahl sollten Anleger verwenden, um zu bestimmen, ob ihre Beteiligungen Meldepflichten gemäß den Offenlegungs- und Transparenzregeln der FCA auslösen. Weitere Finanzdaten, Unternehmensmaßnahmen oder strategische Updates wurden in der Einreichung nicht enthalten.

UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of July 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
            
Form 40-F 
                        
 
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
01 July 2025 - “Total Voting Rights and Capital”
 
99.1
 
 
Haleon plc: Total Voting Rights and Capital
 
1 July 2025: As at 30 June 2025 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 8,988,533,553 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares.
 
Therefore, the number of ordinary shares with voting rights is 8,984,653,348 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
 
Notifiable interests in Haleon may be sent to: company.secretary@haleon.com
 
Amanda Mellor
Company Secretary
 
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: July 01, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary

FAQ

How many Haleon (HLN) shares carry voting rights as of 30 June 2025?

Haleon reports 8,984,653,348 ordinary shares with voting rights.

What is Haleon’s total issued share capital reported in the Form 6-K?

Total issued capital is 8,988,533,553 ordinary shares of £0.01 each.

How many treasury shares does Haleon hold?

The company holds 3,880,205 shares in treasury.

Why is the voting-rights figure important for investors?

Investors use it as the denominator to determine when their holdings reach FCA disclosure thresholds.

What type of filing did Haleon submit?

A Form 6-K, providing an update on total voting rights and share capital.
Haleon

NYSE:HLN

HLN Rankings

HLN Latest News

HLN Latest SEC Filings

HLN Stock Data

46.81B
4.49B
0.02%
11.99%
0.59%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United Kingdom
Weybridge